Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 93% Improvement Relative Risk Death/intubation 84% c19early.org/d Radujkovic et al. Vitamin D for COVID-19 Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Prospective study of 185 patients in Germany Lower mortality (p=0.001) and death/intubation (p=0.001) Radujkovic et al., Nutrients 2020, 12:9, 2757, doi:10.3390/nu12092757 Favors vitamin D Favors control
Vitamin D Deficiency and Outcome of COVID-19 Patients
Radujkovic et al., Nutrients 2020, 12:9, 2757, doi:10.3390/nu12092757
Radujkovic et al., Vitamin D Deficiency and Outcome of COVID-19 Patients, Nutrients 2020, 12:9, 2757, doi:10.3390/nu12092757
Sep 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Observational study 185 patients in Germany shows an association between vitamin D status and severity and mortality. Adjusted hazard ratio of vitamin D sufficiency for combined mechanical ventilation and death was HR 0.16, p < 0.001, and for death HR 0.068, p < 0.001.
risk of death, 93.2% lower, HR 0.07, p = 0.001, high D levels 144, low D levels 12, >30nmol/L.
risk of death/intubation, 84.0% lower, HR 0.16, p < 0.001, high D levels 144, low D levels 12, >30nmol/L.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Radujkovic et al., 10 Sep 2020, prospective, Germany, peer-reviewed, 6 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: nutrients Article Vitamin D Deficiency and Outcome of COVID-19 Patients Aleksandar Radujkovic 1 , Theresa Hippchen 2 , Shilpa Tiwari-Heckler 2 , Saida Dreher 2 , Monica Boxberger 2 and Uta Merle 2, * 1 2 * Department of Internal Medicine V, University of Heidelberg, 69121 Heidelberg, Germany; aleksandar.radujkovic@med.uni-heidelberg.de Department of Internal Medicine IV, University of Heidelberg, 69121 Heidelberg, Germany; theresa.hippchen@med.uni-heidelberg.de (T.H.); shilpa.tiwari-heckler@med.uni-heidelberg.de (S.T.-H.); saida.dreher@med.uni-heidelberg.de (S.D.); monica.boxberger@med.uni-heidelberg.de (M.B.) Correspondence: uta.merle@med.uni-heidelberg.de; Tel.: +49-6221-568705 Received: 9 August 2020; Accepted: 9 September 2020; Published: 10 September 2020   Abstract: Infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses an enormous challenge to health care systems throughout the world. Without causal treatment, identification of modifiable prognostic factors may help to improve outcomes. To explore possible associations of vitamin D (VitD) status with disease severity and survival, we studied 185 patients diagnosed with coronavirus disease 2019 (COVID-19) and treated at our center. VitD status at first presentation was assessed retrospectively using accredited laboratory methods. VitD deficiency was defined as serum total 25-hydroxyvitamin D level < 12 ng/mL (<30 nM). Primary endpoint was severe course of disease (i.e., need for invasive mechanical ventilation and/or death, IMV/D). Within a median observation period of 66 days (range 2–92), 23 patients required IMV. A total of 28 patients had IMV/D, including 16 deaths. Ninety-three (50%) patients required hospitalization (inpatient subgroup). A total of 41 (22%) patients were VitD deficient. When adjusted for age, gender, and comorbidities, VitD deficiency was associated with higher risk of IMV/D and death (HR 6.12, 95% CI 2.79–13.42, p < 0.001 and HR 14.73, 95% CI 4.16–52.19, p < 0.001, respectively). Similar correlations were observed in the inpatient subgroup. Our study demonstrates an association between VitD deficiency and severity/mortality of COVID-19, highlighting the need for interventional studies on VitD supplementation in SARS-CoV-2 infected individuals. Keywords: vitamin D; SARS-CoV-2; COVID-19; outcome; severity; retrospective
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit